EFG
MBRX icon

Ethos Financial Group’s Moleculin Biotech MBRX Stock Holding History

Ethos Financial Group’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-401
Closed -$5.32K – 559
2025
Q3 		$5.32K Buy
+401
New +$5.42K ﹤0.01% 501

Other funds holding MBRX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EI
EFG International Zurich $4.67B AUM
PWPS
Pinnacle Wealth Planning Services Mansfield, Ohio $968M AUM 19.1% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Ethos Financial Group's MBRX Position: Q4 2025 in Review

Ethos Financial Group sold out of Moleculin Biotech (MBRX) in Q4 2025, closing a stake of 401 shares — an estimated $5.32K sold.

Ethos Financial Group first reported a position in MBRX in Q3 2025 and held it in 1 quarter. The position peaked at $5.32K in Q3 2025. 17 funds tracked by Wall St. Rank hold MBRX as of Q4 2025.

  • Ethos Financial Group reported no remaining Moleculin Biotech position as of Q4 2025 after selling out during the quarter.
  • Ethos Financial Group sold 401 Moleculin Biotech shares in Q4 2025, an estimated $5.32K.
  • Ethos Financial Group first reported a position in Moleculin Biotech in Q3 2025 and held it in 1 quarter.
  • Ethos Financial Group's Moleculin Biotech position peaked at $5.32K in Q3 2025.
  • 17 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2025.

Based on Ethos Financial Group's 13F filing for Q4 2025, filed 20 Jan 2026.